Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Issued
Ratios

Akebia Therapeutics (AKBA) Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Leases for 7 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Leases fell 55.43% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 55.43% year-over-year, with the annual reading at $3.7 million for FY2025, 55.43% down from the prior year.
  • Leases for Q4 2025 was $3.7 million at Akebia Therapeutics, down from $4.8 million in the prior quarter.
  • The five-year high for Leases was $33.9 million in Q4 2021, with the low at $3.7 million in Q4 2025.
  • Average Leases over 5 years is $18.0 million, with a median of $13.9 million recorded in 2023.
  • The sharpest move saw Leases skyrocketed 30.81% in 2022, then crashed 59.23% in 2024.
  • Over 5 years, Leases stood at $33.9 million in 2021, then decreased by 13.87% to $29.2 million in 2022, then crashed by 57.42% to $12.4 million in 2023, then plummeted by 33.81% to $8.2 million in 2024, then plummeted by 55.43% to $3.7 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $3.7 million, $4.8 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.